Potential Solutions and Actions & Further Commitment needed to overcome the problems

Associate Professor Dr Liew Su May
Lead of the Malay translation of Testing Treatments
Department of Primary Care Medicine
University of Malaya
Use of thrombolytics (alteplase) in acute ischemic stroke

- Shown to be effective in 1995
- Approved by FDA in 1996
- Endorsed by guidelines in 1997

### Acute Stroke therapy

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Recommendations</th>
<th>Level of evidence</th>
<th>Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>rt-Pa</td>
<td>Intravenous rt-PA (0.9mg/kg, maximum 90mg), with 10% of the dose given as a bolus followed by a 60-minute infusion, is recommended within 4.5 hours of onset of ischaemic stroke. (new recommendation)</td>
<td>I</td>
<td>A</td>
</tr>
</tbody>
</table>
Piracetam Injection

PICATAM

FOR INTRAVENOUS USE

60 ml.
Main results

We included three trials involving 1002 patients, with one trial contributing 93% of the data. Participants' ages ranged from 40 to 85 years, and both sexes were equally represented. Piracetam was associated with a statistically non-significant increase in death at one month (approximately 31% increase, 95% confidence interval 81% increase to 5% reduction). This trend was no longer apparent in the large trial after correction for imbalance in stroke severity. Limited data showed no difference between the treatment and control groups for functional outcome, dependence or proportion of patients dead or dependent. Adverse effects were not reported.

Authors' conclusions

There is some suggestion (but no statistically significant result) of an unfavourable effect of piracetam on early death, but this may have been caused by baseline differences in stroke severity in the trials. There is not enough evidence to assess the effect of piracetam on dependence.
Regulations
Legislations

- Drugs under the purview of the National Pharmaceutical Regulatory Agency
- Regulation of medical devices under Medical Device Act 2012
- Traditional and Complementary Medicine Act 2016 (Control of Drugs and Cosmetics Regulation in 1984)
MAGNETIC POWER
YOUR BODY IS A MAGNETIC FIELD
MAGNETS MAY INTENSIFY
PATIENTS

HEALTH CARE PROVIDERS

RESEARCHERS

TECHNOLOGY DEVELOPERS

HEALTH TECHNOLOGY ASSESSMENTS

PAYERS

POLICY MAKERS

CARERS

PUBLIC
Patient, Carers and Public

• Input to questions, methods, results and assessment
• Improvement in overall health literacy – understand the need to test treatment
• Translation of testing treatment into local languages – Malay translation
Cakap tidak jelas
Perubahan muka
Anggota lemah
Terus ke hospital

KENAL PASTI STROK, C.E.P.A.T KE HOSPITAL
Rawatan paling berkesan dalam tempoh 3 JAM
Health care providers

• Training in EBM and critical appraisal
• Change in attitudes and behaviour
• Incorporation into undergraduate and postgraduate training
• Workshops to teach skills
• Access to information – primary sources/clinical decision support systems/guidance
Researchers

• Data production – use of registries, real-world data
• Data synthesis – skilled information experts, statisticians, health economists, input from practitioners, patients, public.
HTA assessors

• Collaborations – skilled information experts, researchers, statisticians, health economists, input from practitioners, patients, public.
• HTA assessments – independent without conflict of interest, timeliness, transparent
• Not only cost-containment but focus on value
Policy makers and Payers

- Training on evidence and health technology assessment
- Refocus on value
- Provide adequate support – work culture has significant impact
Technology Developers

- Focus is on increasing shareholder value
- Tension due to conflicts of interest
- Need to adhere to legislations and regulations
- If they understand the “rules of the road”, then they can plan accordingly.

Continuing Professional Development

• Malaysia has linked CPD to the renewal of the Annual Practising Certificate and recertification of specialist registration
• Includes publication, reviewing activities and attending CME events
• Mandatory as part of the amendments to the Medical Act 2012

http://cpd.specialist.org.my/
• Monitor outcomes – clinical, costs, resources, equipment, prescriptions etc.
• Check for variation in practice
References